Recro Pharma Company Profile (NASDAQ:REPH)

Analyst Ratings

Consensus Ratings for Recro Pharma (NASDAQ:REPH) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.00 (167.52% upside)

Analysts' Ratings History for Recro Pharma (NASDAQ:REPH)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2015MLV & Co.Boost Price TargetBuy$12.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014AegisDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Recro Pharma (NASDAQ:REPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/12/2016        
5/12/2016Q1($0.66)($0.71)$13.00 million$17.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2016Q4($0.43)$1.13ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.20)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q115($0.52)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2015Q414($0.68)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.51)($0.61)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.25)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.36)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Recro Pharma (NASDAQ:REPH)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Recro Pharma (NASDAQ:REPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Recro Pharma (NASDAQ:REPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/31/2016Stewart MccallumInsiderBuy1,250$8.22$10,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Randall MackVPBuy2,000$6.30$12,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Scp Vitalife Partners (Israel)Major ShareholderSell2,503$6.30$15,768.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Scp Vitalife Partners (Israel)Major ShareholderSell6,260$6.46$40,439.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Winston J ChurchillDirectorSell58,331$7.91$461,398.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Donna NicholsCAOBuy1,140$6.48$7,387.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Scp Vitalife Partners Ii Lpmajor shareholderSell11,385$9.00$102,465.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Scp Vitalife Partners (Israel)major shareholderSell4,393$9.00$39,537.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2015Healthcare Master Fun BroadfinMajor ShareholderBuy646,553$11.60$7,500,014.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Geraldine HenwoodCEOBuy4,500$8.92$40,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Charles GarnerCFOBuy2,000$8.50$17,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Healthcare Master Fun BroadfinMajor ShareholderBuy241,338$2.50$603,345.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Charles GarnerCFOBuy3,000$6.69$20,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Donna NicholsCAOBuy1,200$6.66$7,992.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Recro Pharma (NASDAQ:REPH)
DateHeadline
07/24/16 10:11 AMIs $28 Price Target Attainable For Recro Pharma, Inc. (NASDAQ:REPH)? - Investor Newswire
07/20/16 06:57 PMRecro Pharma Inc Stock Technicals at Critical Inflection Point - CML News
07/19/16 07:04 AMDo Institutional Investors Hate Recro Pharma (NASDAQ:REPH)? - Consumer Eagle
07/17/16 10:12 AMShares Experiencing a Downtrend: Recro Pharma, Inc. (NASDAQ:REPH) - TGP
07/17/16 10:12 AMStrong Sell Calls For Recro Pharma, Inc. (NASDAQ:REPH) At 0 - Investor Newswire
07/13/16 06:28 PMRecro Pharma Incorporated (NASDAQ:REPH) Shorts Decreased by 2.44% After Short Covering - Consumer Eagle
07/11/16 06:01 PMRecro Pharma, Inc. (REPH) Broker Price Targets For The Coming Week - Fiscal Standard
07/10/16 10:06 AMIs $28 Within Reach For Recro Pharma, Inc. (NASDAQ:REPH)? - Investor Newswire
07/08/16 08:58 AMRecro Pharma, Inc. (REPH) Current Analyst Ratings - Fiscal Standard
07/07/16 06:09 PMNew Broker Ratings For Recro Pharma, Inc. (REPH) - FTSE News
07/06/16 10:46 AMBroker Outlook For The Week Ahead Recro Pharma, Inc. (REPH) - Fiscal Standard
07/05/16 03:39 PMRECRO PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
07/05/16 06:19 AM7:19 am Recro Pharma appoints Michael Celano as CFO, effective July 5 -
07/03/16 10:14 AMRecro Pharma Incorporated (NASDAQ:REPH) Sellers Covered 2.44% of Their Shorts - Engelwood Daily
07/01/16 06:07 PMRecro Pharma, Inc. (NASDAQ:REPH) Expected to Reach Highs Of $28 - Investor Newswire
06/27/16 10:15 AMNext Weeks Broker Price Targets For Recro Pharma, Inc. (REPH) - Fiscal Standard
06/24/16 06:10 PMRecro Pharma, Inc. (REPH) Updated Price Targets - FTSE News
06/24/16 06:10 PMStrong Sell Calls Recommendations For Recro Pharma, Inc. (NASDAQ:REPH) At 0 - Investor Newswire
06/18/16 10:13 AMStrong Buy Calls Count For Recro Pharma, Inc. (NASDAQ:REPH) At 2 - Investor Newswire
06/03/16 09:00 AMInsider Transaction: Recro Pharma Inc (NASDAQ:REPH)'s Chief Commercial Officer Fred Graff Paid for 8000 shares - HNN - Insider Transaction: Recro Pharma Inc (NASDAQ:REPH)'s Chief Commercial Officer Fred Graff Paid for 8000 sharesHNNFred Graff; that is an insider in Recro Pharma Inc who is the last to get shares in the firm for which he is presently the Chief Commercial Officer. He in the last few days purchased some 8,000 shares of the company, that are worth around $67,707 U.S ...
06/02/16 06:00 AMRecro Pharma to Present at the Jefferies 2016 Global Healthcare Conference - [GlobeNewswire] - MALVERN, Pa., June 02, 2016-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings that is currently developing non-opioid ...
05/29/16 11:54 AMPerformance at a Glance on Recro Pharma, Inc. (NASDAQ:REPH) - HNN - Performance at a Glance on Recro Pharma, Inc. (NASDAQ:REPH)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Recro Pharma, Inc. (NASDAQ:REPH)'s stock has performed at various points in its past. Currently, the ...and more »
05/25/16 03:05 PMRECRO PHARMA, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, Financial S -
05/25/16 12:28 PMWinston Churchill an Insider in Recro Pharma Inc (NASDAQ:REPH) Sold 58331 Shares of the Company - Wall Street Hints and News - Winston Churchill an Insider in Recro Pharma Inc (NASDAQ:REPH) Sold 58331 Shares of the CompanyWall Street Hints and NewsAs reported in the Washington-based SEC, a legal document for the sale of 58,331 shares of Recro Pharma Inc by Winston Churchill was filled. Winston Churchill is currently the director of the corporation. The document was filled on 23/05/2016. The ...and more »
05/24/16 12:56 PMRecro Pharma, Inc. (NASDAQ:REPH) One-Year Price Projection At $22 - Investor Newswire - Recro Pharma, Inc. (NASDAQ:REPH) One-Year Price Projection At $22Investor NewswireSell-side analysts are certain on the prospect of Recro Pharma, Inc. (NASDAQ:REPH) stock. As of 2016-05-21, the stock ABR stands at 1. This type of rating states that whenever a stock has a score of 5, investors should avoid investing in such stocks.and more »
05/21/16 12:18 PMRevenue Update on Recro Pharma Inc(NASDAQ:REPH) - Trade Calls - Revenue Update on Recro Pharma Inc(NASDAQ:REPH)Trade CallsRecro Pharma Inc(NASDAQ:REPH) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 12, 2016. Company reported revenue of $17.74M. Analysts estimated a revenue of $13.00M. Earnings per share ...Recro Pharma Incorporated (NASDAQ:REPH) Shorted Shares Decreased By 10.96%The Postall 2 news articles »
05/19/16 12:18 PMRecro Pharma Inc Forms Double Bottom Pattern; Strong Momentum for Sellers - Wall Street Hints and News - Recro Pharma Inc Forms Double Bottom Pattern; Strong Momentum for SellersWall Street Hints and NewsThe chart of Recro Pharma Inc (REPH) shows a double bottom with $5.91 target or 11.00% below today's $6.64 share price. The 8 months chart pattern indicates high risk for the $64.00 million company. It was reported on May, 19 by Finviz.com. If the $5 ...
05/17/16 01:17 PMRecro Pharma, Inc. (NASDAQ:REPH) One-Year Mean Price Target At $22 - Investor Newswire - Recro Pharma, Inc. (NASDAQ:REPH) One-Year Mean Price Target At $22Investor NewswireSell-side analysts are confident on the future outlook of Recro Pharma, Inc. (NASDAQ:REPH) stock. As of 2016-05-14, the stock has an ABR of 1 rating, where number 5 denotes a Strong Sell and 1 Strong Buy. The ABR is reached on the basis of estimates of ...and more »
05/17/16 01:17 PMAfter Last Week What Do Analysts Think Of Recro Pharma, Inc. (REPH) - Share Trading News - After Last Week What Do Analysts Think Of Recro Pharma, Inc. (REPH)Share Trading News12/09/2014 – Recro Pharma, Inc. had its “hold” rating reiterated by analysts at Aegis Capital. The share price of Recro Pharma, Inc. (REPH) was up +0.15% during the last trading session, with a day high of 6.70. 22690 shares were traded on Recro Pharma ...and more »
05/12/16 08:35 AMRECRO PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan -
05/12/16 08:16 AMRecro Pharma reports 1Q loss -
05/12/16 08:07 AMRecro Pharma Reports First Quarter 2016 Financial Results - [GlobeNewswire] - Enrollment on track in two pivotal Phase III IV meloxicam trials. One trial expected to report top-line results by end of Q3; Other trial to report top-line results by end of Q4. Manufacturing business ...
05/12/16 08:00 AMRecro Pharma Presents Clinical Data at American Pain Society 35th Annual Scientific Meeting - [GlobeNewswire] - MALVERN, Pa., May 12, 2016-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company developing non-opioid products for the treatment of serious acute pain, today announced a poster presentation ...
05/02/16 06:30 AMRecro Pharma, Inc. (NASDAQ:REPH) ABR Of 1 - Investor Newswire - Recro Pharma, Inc. (NASDAQ:REPH) ABR Of 1Investor NewswireThere are numerous brokerages operating in the market, and each one of them uses a different process to prepare the research reports on a stock. As a result, investors have to study more than one research report before taking an investment call on a stock.and more »
05/01/16 06:32 AMBuy Calls For Recro Pharma, Inc. (NASDAQ:REPH) Stands At 0 - Investor Newswire - Buy Calls For Recro Pharma, Inc. (NASDAQ:REPH) Stands At 0Investor NewswireThe Buy calls for Recro Pharma, Inc. (NASDAQ:REPH) stock is 0, sell recommendations at 0 and hold recommendations at 0. It boasts a total of 2 Strong Buy calls and 0 Strong Sell calls as of 2016-04-29. The strong buy calls one month ago were 2 and ...and more »
04/30/16 06:38 AMBroker Roundup For Recro Pharma, Inc. (REPH) - Share Trading News - Broker Roundup For Recro Pharma, Inc. (REPH)Share Trading News12/09/2014 – Recro Pharma, Inc. had its “hold” rating reiterated by analysts at Aegis Capital. The share price of Recro Pharma, Inc. (REPH) was up +0.00% during the last trading session, with a day high of 7.07. 21718 shares were traded on Recro Pharma ...
04/29/16 11:04 AMRECRO PHARMA, INC. Files SEC form 8-K/A, Financial Statements and Exhibits -
04/29/16 07:10 AMRecro Pharma, Inc. (NASDAQ:REPH) Basic Consolidated EPS At $0.3572 - RealistInvestor.com - Recro Pharma, Inc. (NASDAQ:REPH) Basic Consolidated EPS At $0.3572RealistInvestor.comThe basic per-share earnings from continuing operations as confirmed by Recro Pharma, Inc. (NASDAQ:REPH) for the period closed 2015-12-31 was $0.3572. For the quarter ended 2015-12-31, this number was $0.3572. For any specified company's stock ...
04/24/16 06:39 AMCan Shares Of Recro Pharma, Inc. (NASDAQ:REPH) Hit $28? - Stocks Daily - Can Shares Of Recro Pharma, Inc. (NASDAQ:REPH) Hit $28?Stocks DailyZacks rating methodology gives a rating to stock on a 1-5 scale, where a towards the 1-2 band means a Buy call, score of 3 implies a Hold call while a score of 4 to 5 shows Sell consensus. The Buy recommendations for Recro Pharma, Inc. (NASDAQ:REPH) ...and more »
04/22/16 07:27 AMAnalyst Review: Recro Pharma, Inc. (REPH) - Risers & Fallers - Analyst Review: Recro Pharma, Inc. (REPH)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Recro Pharma, Inc. (REPH). According to the latest broker reports outstanding on Thursday 21st of April, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...
04/13/16 12:44 PMAnalysts Expect Recro Pharma Inc (NASDAQ:REPH) to Announce ($0.36) Earnings Per Share - Washington News Wire - Washington News WireAnalysts Expect Recro Pharma Inc (NASDAQ:REPH) to Announce ($0.36) Earnings Per ShareWashington News WireRecro Pharma logo Recro Pharma Inc (NASDAQ:REPH) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock ...Latest Analyst Reports On Recro Pharma, Inc.Risers & FallersWhat's Propelling Recro Pharma Inc to Decline So Much?Stock Callerall 4 news articles »
04/11/16 01:31 PMRecro Pharma, Inc. (REPH) Broker Price Targets For The Coming Week - Share Trading News - Recro Pharma, Inc. (REPH) Broker Price Targets For The Coming WeekShare Trading NewsRecently some investment brokers have made changes to their outstanding price targets on shares of Recro Pharma, Inc. (REPH). According to data from Reuters, 1 analyst has a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, 0 analysts ...and more »
04/09/16 09:50 AMRecro Pharma, Inc. (REPH) Latest Broker Coverage - Risers & Fallers - Recro Pharma, Inc. (REPH) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Recro Pharma, Inc. (REPH). According to the latest broker reports outstanding on Friday 8th of April, 1 analyst has a rating of “strong buy”, 1 analysts “buy”, 0 ...Recro Pharma Incorporated (NASDAQ:REPH) Shorted Shares Decreased By 7.76%Stock Callerall 2 news articles »
04/07/16 07:40 AMRecro Pharma (REPH) Looks Good: Stock Adds 5% in Session -
04/06/16 03:28 PMRecro Pharma, Inc.: Strong price momentum but will it sustain? -
04/06/16 12:36 PMRecro Pharma Inc (NASDAQ:REPH)'s Company Shares Increased 13.46% After High Volatility - Stock Caller - Recro Pharma Inc (NASDAQ:REPH)'s Company Shares Increased 13.46% After High VolatilityStock CallerThe shares of Recro Pharma Inc (NASDAQ:REPH) increased by 13.46% in the last 20 days and rose 14.79% in the past 5 trading sessions. Recro Pharma Inc (NASDAQ:REPH) shares opened at $6.41 in the last session and had intraday high of $6.89 and ...Market Movers: Recro Pharma, Inc. (NASDAQ:REPH), Gerdau S.A. (NYSE:GGB), Domino's Pizza, Inc. (NYSE:DPZ ...KC Registerall 2 news articles »
04/06/16 12:36 PMLatest Analyst Reports On Recro Pharma, Inc. - Risers & Fallers - Latest Analyst Reports On Recro Pharma, Inc.Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Recro Pharma, Inc. (REPH). The latest broker reports which have been released state 1 analyst has a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, 0 analysts ...
04/05/16 12:01 PMMarket Movers: Recro Pharma, Inc. (NASDAQ:REPH), Gerdau S.A. (NYSE:GGB), Domino's Pizza, Inc. (NYSE:DPZ ... - KC Register - Market Movers: Recro Pharma, Inc. (NASDAQ:REPH), Gerdau S.A. (NYSE:GGB), Domino's Pizza, Inc. (NYSE:DPZ ...KC RegisterRecro Pharma, Inc. (NASDAQ:REPH) reported financial results for the year ended December 31, 2015. Revenues and COGS for the period from April 10, 2015 through December 31, 2015 were $52.0 million and $28.1 million, respectively. There were no ...
04/05/16 12:01 PMBiggest Movers in Manufacturing Stocks Now – ICPT REPH ZYNE VRX - Recro Pharma Inc (REPH): REPH stock is up 13.47% today. Zynerba Pharma CS (ZYNE): ZYNE stock is up 10.75% today. Valeant Pharmaceuticals International (VRX): VRX stock is up 10.46% today. Oasmia Pharmaceu Ads (OASM): OASM stock is up 7.93% today.
03/29/16 12:04 PMRECRO PHARMA, INC. Financials -

Social

About Recro Pharma

Recro Pharma logoRecro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. The Company's lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN, Dex-SL and Fadolmidine (Fado). Dex-IN is a product candidate under development for the treatment of post-operative pain and for the treatment of cancer breakthrough pain. Dex-SL is a product candidate for the treatment of chronic pain. Fado is a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: REPH
  • CUSIP:
Key Metrics:
  • Previous Close: $7.85
  • 50 Day Moving Average: $8.055
  • 200 Day Moving Average: $7.246
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $74.78M
  • Beta: -1.2
  • Current Year EPS Consensus Estimate: $-3.41 EPS
  • Next Year EPS Consensus Estimate: $-2.85 EPS
Additional Links:
Recro Pharma (NASDAQ:REPH) Chart for Monday, July, 25, 2016